List view / Grid view
Ali Shilatifard’s article explains how investment in institutes performing molecular research is essential, as it is the foundation for all attempts to combat COVID-19 and other future pandemics.
Exploring how therapies with multi-faceted approaches could improve options for treatment-refractory cancers, like pancreatic and triple-negative breast cancer.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.
Glycomimetics, a novel class of antivirals, prevented influenza, herpes viruses and papillomaviruses from infecting cells in animal models and could show similar efficacy against COVID-19.
A study has shown that the COVID-19 pandemic has resulted in a high level of research donations, making the condition the third most funded disease on average by year.
The developers of a novel method to create immunological assay probes for screening T cells has leveraged their new protocol against COVID-19.
Using cyro-electron microscopy, researchers have imaged the binding site between a molecule and the tumour suppressor protein PP2A, enabling optimisation of the drug compound.
Novel promoters based on those in the herpes viruses, enabled delivery of larger genes and increased the period they were active in the nervous system.
Researchers comparing the effects of SARS-CoV-2, SARS-CoV and MERS-CoV in cynomolgus macaques suggest they could be an effective animal model for testing COVID-19 therapeutics.
An Ebola vaccine that has been tested in animals could potentially be used to neutralise four species of the virus, say the researchers.
Researchers demonstrated NSPP completely prevented cognitive decline in mice treated with radiation for patient-derived glioblastomas.
Researchers have made the genome of the Nicotiana benthamiana plant, a commonly used bio-factory organism, public to aid in COVID-19 vaccine production.
The developers of the lung epithelium model plan to investigate whether SARS-CoV-2 can infect and replicate in the model to assess whether it could be used in the fight against COVID-19.
The vaccine candidate protected all murine models from a lethal MERS infection and could also be effective against the SARS-CoV-2 virus causing COVID-19.
Collaborators have shown that the broad spectrum oral antiviral EIDD-2801 could be a potential prophylactic or therapeutic for COVID-19 and other coronaviruses.
